Abstract: The present invention relates to a light emitting metallic compound of Chemical Formula 1 and an organic electroluminescence device including the compound. In the Chemical Formula 1, M is selected from Ir, Pt, Rh, Re, and Os, and m is 2, provided that m is 1 when M is Pt.

Abstract: The present invention relates to the use of copper(I) complexes of the formula I where X is nitrogen or a C—R group, R is alkyl or aryl, Ar is phenyl or naphthyl, each of which is optionally substituted by from one to three radicals selected from the group consisting of alkoxy, alkylthio, alkylamino, dialkylamino, alkoxycarbonyl, alkoxysulfonyl, halogen, cyano, carboxyl, hydroxysulfonyl and nitro, and the two optionally substituted phenyl or naphthyl radicals may be joined to one another by a chemical single bond via the carbon atoms in the ?- and ??-position relative to the phosphorus atom, n is 1, 2 or 3, and Y is halogen, cyano, thiocyanato, alkoxy, aryloxy, alkylthio, arylthio, alkylamino, dialkylamino, arylamino or diarylamino, in organic light-emitting diodes (OLEDs), The present invention further relates to light-emitting layers which comprise at least one copper(I) complex of the formula I, to OLEDs which comprise at least one copper(I) complex of the formula I or an inventive light-em

Abstract: An organic radiation-emitting component such as an organic light emitting diode (OLED), having at least two electrode layers and, between them, at least one organic self-emitting layer with a phosphorescence triplet emitter comprising as well as one phosphorescent metal complex. The radiation-emitting layer contains, embedded in a matrix, a metal complex, preferably a transition metal complex, with at least one substituted or unsubstituted guanidinate ligand.

Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

Abstract: Novel N-heterocyclic carbene ligand precursors, N-heterocyclic carbene ligands and N-heterocyclic metal-carbene complexes are provided. Metal-carbene complexes comprising N-heterocyclic carbene ligands can be chiral, which are useful for catalyzing enantioselective synthesis. Methods for the preparation of the N-heterocyclic carbene ligands and N-heterocyclic metal-carbene complexes are given.

Abstract: A photosensitizing transition metal complex of the formula (Ia) MLY1, (Ib) MLX3 (Ic) MLY2X, (Id) MLY3X or (Ie) MLY4X in which M is a transition metal selected from ruthenium, osmium, iron, rhenium and technetium, preferably ruthenium or osmium. X is a co-ligand independently selected from NCS—, Cl—, Br—, I—, CN—, H2O; pyridine unsubstituted or substituted by at least one group selected from vinyl, primary, secondary or tertiary amine, OH and C1-30 alkyl, preferably NSC and CN—; L is a tridentate polypyridine ligand, carrying at least one carboxylic, phosphoric acid or a chelating group and one substituted or unsubstituted alkyl group having 1 to 50 carbon atoms, substituted or unsubstituted alkylamide group having 2 to 30 carbon atoms or substituted or unsubstituted aralkyl group having 7 to 50 carbon atoms.

Abstract: It is an object of the present invention to obtain an organometallic complex that is capable of converting an excited triplet state into luminescence, a light-emitting element that can be driven for a long time, is high in luminous efficiency, and has a favorable long lifetime, and a light-emitting device using the light-emitting element. The present invention provides a light-emitting element that has a pair of electrodes (an anode and a cathode) and a light-emitting layer between a pair of electrodes, where the light-emitting layer includes an organometallic complex represented by the following general formula (5) and one of a compound that has a larger energy gap than the organometallic complex and a compound that has a larger ionization potential and a smaller electron affinity than the organometallic complex, and provides a light-emitting device using the light-emitting device.

Abstract: The invention provides an organometallic complex having Formula (I): wherein each of N?C bidentate ligands independently is: an N?O bidentate ligand is: R1 to R10 each independently are H, alkyl, alkenyl, alkynyl, CN, CF3, alkylamino, amino, alkoxy, halo, aryl, or heteroaryl.

Abstract: The invention relates to a compound which has affinity with amyloid, shows sufficiently rapid clearance from normal tissues and is suppressed in toxicity such as mutagenicity, and also relates to a low-toxic diagnostic agent for Alzheimer's disease containing the compound. The compound is represented by the following formula (1) or a salt thereof: wherein A1, A2, A3 and A4 independently represent a carbon or a nitrogen, and R3 is a group represented by the following formula: wherein R1 is a radioactive halogen substituent; m is an integer of 0 to 4; and n is an integer of 0 or 1, provided that at least one of A1, A2, A3 and A4 represents a carbon, and R3 binds to a carbon represented by A1, A2, A3 or A4.

Abstract: Phenanthroline-comprising complexes and catalyst systems obtained therefrom, and also their use in the polymerization of olefins.

Abstract: [Problem] The present invention aims to provide a novel organometallic compound that can be used as a general-use highly active catalyst with superior selectivity for functional groups. [Means for Solving Problem] The present invention relates to an organometallic compound having a novel specific structure of general formula (1): and to a general-use highly active catalyst used in reductive amination reaction with superior selectivity for functional groups that comprises said organometallic compound, and to a process for preparing amine compounds by reductive amination reaction using said catalyst.

Abstract: The present invention provides a compound represented by the formula (I): wherein ring A is void or a benzene ring optionally having substituent(s), R1 and R2 are each independently a phenyl group optionally having substituent(s), a cyclohexyl group and the like, R3 and R4 are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group and the like, and X is a residue represented by —OR5 or —NHR6 wherein R5 and R6 are a lower alkyl group optionally having substituent(s), an aralkyl group optionally having substituent(s) and the like, a asymmetric transition metal complex containing the compound as a ligand and a production method of optically active compound using the complex as an asymmetric catalyst.

Abstract: Transition metal complexes include a diazaphosphacycle of formula III and a transition metal. The phosphorus atom of the diazaphosphacycle is bonded to the transition metal and the diazaphosphacycle of formula III has the following structure where the variables have the values set forth herein.

Abstract: In accordance with the present invention there are provided sterically demanding intercalators. These compounds are useful for detection of a base-pair mismatch, such as by measuring fluorescence of complexes formed by the compounds of the invention and nucleic acid duplexes. The compounds are also capable of catalyzing photolytic cleavage of nucleic acids.

Abstract: The present invention relates to a co-culture method of Sphingomonas sp. bacterial strain and Aspergillus sp. fungus strain, in which the novel Sphingomonas sp. bacterial strain KMK-001 is cultured in a liquid medium and the novel Aspergillus sp. strain KMC-901 separately cultured in another liquid medium is added to the above culture solution, a novel glionitrin biosynthesized therefrom and a pharmaceutical composition comprising the said glionitrin or its pharmaceutically acceptable salt as an active ingredient. The glionitrin herein has strong cytotoxic effect on cancer cells and has antibiotic effect on 10 pathogenic bacteria including the novel Sphingomonas sp. bacterial strain KMK-001, so that it can be effectively applied in antibiotics or anti-cancer agents.

Abstract: The invention relates to hybrid organic-inorganic materials containing molybdenum and having photochromic properties. The invention also relates to the use thereof, particularly in cosmetics and in the glass industry, e.g. in glazing applications or in the production of ocular glasses.

Abstract: This inventive subject matter relates to novel transitional metal complexes of Quinoxalines, methods for making such compounds, and methods for using such compounds for treating diseases and disorders mediated by kinase activity. The present invention relates to new substituted Quinoxaline compounds, their tautomers, stereoisomers, polymorphs, esters, metabolites, and prodrugs, to the pharmaceutically acceptable salts of the compounds, tautomers, stereoisomers, polymorphs, esters, metabolites, and prodrugs, to compositions of any of the aforementioned embodiments together with pharmaceutically acceptable carriers, and to uses of any of the aforementioned embodiments, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cancer.

Abstract: Compounds for antimicrobial applications, and for treating bacterial and fungal infection are set forth. The compounds may include a metal complex incorporated into a biodegradable polymeric nanoparticle. Also, a method of treating bacterial and fungal infections in a mammal includes the steps of administering an effective amount of a silver(I) metal salt incorporated into a biodegradable polymeric nanoparticle.

Abstract: The invention relates to nanoparticles made from organometallic hybrid materials made from iron carboxylates, used for example as contrast agents. The particles can also be used for the encapsulation and vectoring of molecules of interest such as active3 pharmaceutical agents, cosmetically interesting compounds and markers. Apart from the intrinsic properties thereof for imaging, said nanoparticles give good results in terms of capacity for loading with medicaments and in biocompatibility.

Abstract: It is an object of the present invention to provide a substance that can emit phosphorescence. Further, it is an object of the present invention to provide a light emitting element with favorable color purity. The present invention provides an organometallic complex having a structure represented by a general formula (1). A light emitting element that can exhibit red or reddish emission of light with favorable color purity can be obtained by using the organometallic complex of the present invention as aluminescent substance. In addition, a light emitting element that can emit light efficiently can be obtained by using the organometallic complex of the present invention as a sensitizer.

Abstract: The disclosure provides zeolitic frameworks for gas separation, gas storage, catalysis and sensors. More particularly the disclosure provides zeolitic frameworks (ZIFs). The ZIF of the disclosure comprises any number of transition metals or a homogenous transition metal composition.

Abstract: The subject invention concerns methods and materials for cancer screening using platinum complexes to detect a STAT protein biomarker. Platinum (IV) complexes interacting with STATs directly correlate with the STAT expression. In one embodiment, fluorescently-labeled and/or antibody-linked platinum (IV) complexes can be used to assess the STAT expression and define malignant potential. Other methods such as imaging (MRI, e.g.) can also be used to assess platinum-STAT interactions. The STAT protein can be, for example, STAT3.

Abstract: To provide a novel organometallic complex capable of emitting phosphorescence by using an organic compound with which a variety of derivatives can be easily synthesized as a ligand. In addition, to provide an organometallic complex which exhibits red emission. To provide an organometallic complex formed by ortho-metalation of an m-alkoxyphenyl pyrazine derivative represented by General Formula (G0) below with respect to an ion of a metal belonging to Group 9 or Group 10. In addition, to provide an organometallic complex which exhibits red emission formed by ortho-metalation of an m-alkoxyphenyl pyrazine derivative represented by General Formula (G0) below with respect to an ion of a metal belonging to Group 9 or Group 10.

Abstract: There is disclosed herein phosphorescent compounds, uses thereof, and devices including organic light emitting diode (OLEDs) including such compounds. Compounds of interest include: wherein A is Os or Ru The anionic chelating chromophores N^N, which are formed by connecting one pentagonal ring structure containing at least two nitrogen atoms to a hexagonal pyridine type of fragment via a direct carbon-carbon linkage. L is a neutral donor ligand; the typical example includes carbonyl, pyridine, phosphine, arsine and isocyanide; two neutral L's can also combine to produce the so-called chelating ligand such as 2,2?-bipyridine, 1,10-phenanthroline and N-heterocyclic carbene (NHC) ligand, or bidentate phosphorous ligands such as 1,2-bis(diphenylphosphino)ethane, 1,2-bis(diphenylphosphino)benzene. L can occupy either cis or trans orientation.

Abstract: An organic electroluminescent device comprising a pair of electrodes and at least one organic layer between the pair of electrodes, wherein the organic layer contains at least one compound represented by the formula (I), preferably by the formula (II) and more preferably by the formula (III) as defined herein.

Abstract: A light-emitting material comprising a compound having a partial structure represented by following formula (21) or a tautomer thereof:

Abstract: A synthesis method of a compound having a partial structure represented by following formula (21) or a tautomer thereof, the method comprising reacting at least one of a ligand and a dissociation product thereof with an iridium compound at a room temperature or at an elevated temperatures in the presence or absence of a solvent or in the presence or absence of a base:

Abstract: Complexes of ruthenium and osmium according to the invention are represented by formula (1), in which M denotes ruthenium or osmium, L denotes a neutral ligand selected from the group comprising amines, imines, phosphines (preferably stilbines, arsines, alcohols, thiols, ethers and thioethers or an N-heterocyclic carbene (NHC) ligand). The compounds of formula (1) occur in the form of two isomers: trans and cis. The method of production of complexes of ruthenium and osmium of formula (1) according to the invention is based on reacting an intermediate of formula (5) with a carbene complex of ruthenium or osmium. The invention also relates to the use of the complexes according to the invention for carrying out metathesis reactions.

Abstract: A compound represented by following formula (23): wherein R11 and R12 each represents a substituent; R13, R14 and R15 each represents a hydrogen atom or a substituent; m1 represents an integer of from 0 to 4; and m2 represents an integer of from 0 to 6.

Abstract: The present invention provides novel organic molybdenum compounds, the use thereof as friction-modifiers and lubricating compositions which contain said compounds. The organic molybdenum compounds can be represented by the general formula (1) which is indicated below, wherein A1 and A2 are heterocyclic rings which may have substituent groups.

Abstract: An organometallic complex having a structure represented by the general formula (G1) is synthesized and applied to a light-emitting element. In the formula, R3 represents either an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, or an alkoxycarbonyl group having 1 to 5 carbon atoms; R2 and R3 each show either hydrogen or an alkyl group 1 to 4 carbon atoms; Ar represents an arylene group having 6 to 25 carbon atoms; M is a center metal selected from Group 9 element and Group 10 element.

Abstract: The invention is related to compounds of Formula I: or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Abstract: The present invention provides bipyrimidinyl diphosphine compounds of the formula wherein R is optionally substituted alkyl, cycloalkyl, aryl or heteroaryl; R? and R? are independently optionally substituted alkyl, cycloalkyl, aryl or heteroaryl; or an enantiomer thereof; or an enantiomeric mixture thereof. The compounds of the formula (I) are chiral atropisomeric bipyrimidinyl diphosphine compounds and, thus, may be employed as ligands to generate chiral transition metal catalysts which may be applied in a variety of asymmetric reactions, e.g., in palladium catalyzed asymmetric allylic substitution reactions. The compounds of the present invention are easily accessible in high enantiomeric purity according to the methods disclosed herein.

Abstract: The present invention describes novel organometallic compounds which are phosphorescence emitters. Such compounds can, as active constituents (=functional materials), be used in a number of different applications, which in the broadest sense can be classed as belonging to the electronics industry. The compounds according to the invention are described by the formulas (I), (Ia), (II), (IIa), (III), (IIIa), (IV) and (IVa).

Abstract: This invention relates to electroluminescent metal complexes with benzotriazoles of the formula (I), a process for their preparation, electronic devices comprising the metal complexes and their use in electronic devices, especially organic light emitting diodes (OLEDs), as oxygen sensitive indicators, as phosphorescent indicators in bioassays, and as catalysts.

Abstract: An organometallic complex is provided by which favorable red-color light emission can be obtained. Further, an organometallic complex having a peak of light emission at about 620 nm is provided because the wavelength of light which is perceived as excellent red-color light is about 620 nm. Furthermore, an organometallic complex is provided by which red-color light emission with high luminous efficiency (cd/A) can be obtained. An organometallic complex represented by the following general formula (G2) and a light-emitting element, a light-emitting device, and an electronic device including the organometallic complex represented by the following general formula (G2) are provided.

Abstract: Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by overexpression of seprase include complexes that contains a proline moiety and a radionuclide adapted for radioimaging and/or radiotherapy:

Abstract: Use of metal complex compounds of formula [LnMemXp]zYq??(1), wherein Me is manganese, titanium, iron, cobalt, nickel or copper, X is a coordinating or bridging radical, n and m are each independently of the other an integer having a value of from 1 to 8, p is an integer having a value of from 0 to 32, z is the charge of the metal complex, Y is a counter-ion, q=z/(charge Y), and L is a ligand of formula wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are each independently of the others hydrogen; unsubstituted or substituted C1-C18alkyl or aryl; cyano; halogen; nitro; —COOR12 or —SO3R12 wherein R12 is in each case hydrogen, a cation or unsubstituted or substituted C1-C18alkyl or aryl; —SR13, —SO2R13 or —OR13 wherein R13 is in each case hydrogen or unsubstituted or substituted C1-C18alkyl or aryl; —N(R13)—NR?13R?13 wherein R13, R?13 and R?13 are as defined above for R13; —NR14R15 or —N?R14R15R16 wherein R14, R15 and R16 are each independently of the other(s) hydrogen or unsubstituted or substit

Abstract: A self-decontaminating metal organic framework including an acid linked to a metal producing a metal organic framework configured for the sorption of chemical warfare agents and/or toxic industrial chemicals, the metal organic framework including reactive sites for the degradation of the agents and chemicals.

Abstract: Process for preparing pigments of the formula (I) or tautomeric structures thereof and their hydrates, containing melamine as guest, characterized in that a mixture of the azobarbituric mono-cation salt (II) and the azobarbituric di-cation salt (III) is reacted with a nickel compound and melamine, in which cation1, cation2 and cation3 independently of one another are any desired univalent cations or the fraction of any desired multivalent cation that corresponds to a positive charge of one.

Abstract: An anticancer agent having a novel chemical structure and high anticancer activity is provided. A phosphine transition metal complex of general formula (1) and an anticancer agent containing the complex are disclosed. R1 and R2, which may be the same or different, each represent a group having 1 to 10 carbon atoms selected from a straight-chain or branched alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an adamantyl group, a phenyl group, and a substituted phenyl group; R3 and R4, which may be the same or different, each represent a hydrogen atom, a straight-chain alkyl group having 1 to 6 carbon atoms or branched alkyl group having 1 to 6 carbon atoms; or R3 and R4 are taken together to form a saturated or unsaturated ring which may have a substituted group; M represents a transition metal atom selected from the group consisting of gold, copper, and silver; and X? represents an anion.

Abstract: The present invention relates to novel organic electroluminescent compounds, and organic electroluminescent devices employing the same as electroluminescent material. Specifically, the organic electroluminescent compounds according to the invention are characterized in that they are represented by Chemical Formula (1). Since the organic electroluminescent compounds according to the invention have good luminous efficiency and excellent life property of material, OLED's having very good operation life can be manufactured therefrom.

Abstract: Provided herein is dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon. Also provided herein is the compound dipterinyl calcium pentahydrate (DCP) or an analog or polymorph thereof.

Abstract: The invention provides a cyclometallated complex comprising the structure of formula I wherein: M is a d-block transition metal; B is a five- or six-membered aryl or heteroaryl ring which is optionally substituted and optionally fused to one or more other aryl or heteroaryl rings; A is a five- or six-membered heteroaryl ring comprising at least three nitrogen atoms; R1 is a group other than hydrogen; n is zero or an integer equal to or greater than one; and A and B are optionally fused or linked by one or more covalent bonds. The invention also provides the use of such complexes in optoelectronic devices, and in particular in organic light emitting devices.

Abstract: It is an object of the present invention to provide a substance which can emit red phosphorescence which is closer to the chromaticity coordinates of red according to the NTSC standard. The present invention provides an organometallic complex represented by the general formula (1), wherein each of R1 to R3 represents any one of hydrogen, a halogen group, an acyl group, an alkyl group, an alkoxyl group, an aryl group, a cyano group, and a heterocyclic group, and at least one of R1 to R3 represents an electron-withdrawing group; and M represents a Group 9 element or a Group 10 element, and when M is the Group 9 element, n=2, whereas when M is the Group 10 element, n=1. Such an organometallic complex can emit red phosphorescence with good spectral luminous efficiency which is closer to the chromaticity coordinates of red according to the NTSC standard.

Abstract: The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.

Abstract: Disclosed are an organometallic complex emitting red light with high color purity. An organometallic complex having a structure represented by the following general formula (G1) is provided. In the formula, of R1 to R13, at least one represents an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms and the other or others represent hydrogen. M represents a central metal, which is a Group 9 or Group 10 element. L represents a monoanionic ligand, and n is 2 when the central metal is a Group 9 element or 1 when the central metal is a Group 10 element.

Abstract: A metal-complex compound which comprises a tridentate chelate ligand having a specified partial structure. An organic electroluminescence device which comprises at least one organic thin film layer sandwiched between a pair of electrode consisting of an anode and a cathode, wherein the organic thin film layer comprises the metal-complex compound, which emits light by applying an electric voltage between the pair of electrode. The present invention provides an organic EL device which emits blue light with high purity and of short wavelength with an enhanced efficiency of light emission.

Abstract: Disclosed are 2-quinoxalinol salen compounds and in particular 2-quinoxalinol salen Schiff-base ligands. The disclosed 2-quinoxalinol salen compounds may be utilized as ligands for forming complexes with cations, and further, the formed complexes may be utilized as catalysts for oxidation reactions. The disclosed 2-quinoxalinol salen compounds also may be conjugated to solid supports and utilized in methods for selective solid-phase extraction or detection of cations.

Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.